<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        447-212-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        FLOXAG 320MG F.C. TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        GEMIFLOXACIN MESILATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        320
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        7
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        74.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01MA15 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; FLOXAG contains Gemifloxacin as an active ingredient, which is is a fluoroquinolone antibiotic&nbsp;that fights bacteria in the body.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; FLOXAG is used to treat different types of bacterial infections in the&nbsp;lungs.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fluoroquinolone antibiotics can cause serious or disabling side effects.&nbsp;FLOXAG should be used only for infections that cannot be treated with a safer antibiotic.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; FLOXAG may also be used for purposes not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>FLOXAGcan cause serious side effects,&nbsp;including tendon problems, nerve damage, serious mood or behavior changes, or low blood sugar.</p><p><strong>Stop taking this medicine and call your doctor at once</strong> if you have symptoms such as:&nbsp;headache, hunger, irritability, feeling anxious or shaky, numbness, tingling, burning pain, confusion, agitation, paranoia, problems with memory or concentration, or thoughts of suicide.</p><p>FLOXAG may cause swelling or tearing of a tendon. Stop taking FLOXAG and call your doctor at once if you have sudden pain, swelling, bruising, tenderness, stiffness, or movement problems in any of your joints.</p><p>You should not use this medicine if you are allergic to FLOXAG or other fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin, ofloxacin, norfloxacin, and others).</p><p>FLOXAG may cause swelling or tearing of a tendon (the fiber that connects bones to muscles in the body), especially in the achilles&#39; tendon of the heel. This can happen during treatment or up to several months after you stop taking FLOXAG. Tendon problems may be more likely to occur if you are over 60, if you take steroid medication, or if you have had a kidney, heart, or lung transplant.</p><p>Tell your doctor if you have ever had:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tendon problems, arthritis or other joint problems;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diabetes;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A muscle or nerve disorder, such as myasthenia gravis;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Slow heartbeats or other heart rhythm disorder (especially if you take medication to treat it);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Long QT syndrome (in you or a family member);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Trouble swallowing pills;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver or kidney disease;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Epilepsy or other seizure disorder; or</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low levels of magnesium or potassium in your blood.</p><p>It is not known whether this medicine will harm an unborn baby. Tell your doctor if you are pregnant.</p><p>You should not breast-feed while using FLOXAG.</p><p><strong>Warnings and precautions</strong></p><p>FLOXAG is not approved for use by anyone younger than 18 years old.</p><p>Do not take FLOXAG with dairy products such as milk or yogurt, or with calcium-fortified juice. You may eat or drink these products as part of a regular meal, but do not use them alone when taking FLOXAG. They could make the medication less effective.</p><p>Antibiotic medicines can cause diarrhea, which may be a sign of a new infection. If you have diarrhea that is watery or bloody, call your doctor before using anti-diarrhea medicine.</p><p>FLOXAG could make you sunburn more easily. Avoid sunlight or tanning beds. Wear protective clothing and use sunscreen (SPF 30 or higher) when you are outdoors. Tell your doctor if you have severe burning, redness, itching, rash, or swelling after being in the sun.</p><p><strong>FLOXAG and other medicines</strong></p><p>Some medicines can make FLOXAG much less effective when taken at the same time.&nbsp;If you take any of the following medicines, take your FLOXAG dose 2 hours before or 3 hours after you take the other medicine:</p><ul><li>Antacids&nbsp;that contain magnesium or aluminum ,or the ulcer medicine&nbsp;sucralfate</li><li>Didanosine powder or chewable tablets; or</li><li>Vitamin or mineral supplements that contain aluminum, iron, magnesium, or&nbsp;zinc.</li></ul><p>FLOXAG can cause a serious heart problem.&nbsp;Your risk may be higher if you also use certain other medicines for infections,&nbsp;asthma, heart problems,&nbsp;high blood pressure, depression,&nbsp;mental illness, cancer,&nbsp;malaria, or&nbsp;HIV.</p><p>Tell your doctor about all your other medicines, especially:</p><ul><li>Probenecid;</li><li>A&nbsp;diuretic&nbsp;or &quot;water pill&quot;;</li><li>insulin&nbsp;or oral diabetes medicine (check your blood sugar regularly);</li><li>A blood thinner--warfarin,&nbsp;coumadin,&nbsp;jantoven;</li><li>NSAIDs (nonsteroidal anti-inflammatory drugs)--aspirin, ibuprofen,&nbsp;naproxen&nbsp;, celecoxib,&nbsp;diclofenac, indomethacin,&nbsp;meloxicam, and others; or</li><li>Steroid medicine--prednisone,&nbsp;methylprednisolone, and others.</li></ul><p>This list is not complete. Other drugs may interact with FLOXAG, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow all directions on your prescription label. Use the medicine exactly as directed.</p><p>Take FLOXAG with water, and drink extra fluids to keep your kidneys working properly while taking this medicine.</p><p>Take the medicine at the same time each day, with or without food.</p><p>Swallow the tablet whole and do not chew it.</p><p>Use this medicine for the full prescribed length of time, even if your symptoms quickly improve. Skipping doses can increase your risk of infection that is resistant to medication. FLOXAGwill not treat a&nbsp;viral infection&nbsp;such as the flu or a&nbsp;common cold.</p><p><strong>What happens if you miss a dose?</strong></p><p>Take the medicine as soon as you can, but skip the missed dose if it is almost time for your next dose. Do not take two doses at one time.</p><p><strong>What happens if you overdose?</strong></p><p>Seek emergency medical attention at once.</p><p><strong>Driving &amp; Using Machines</strong></p><p>Avoid driving or hazardous activity until you know how this medicine will affect you. Your reactions could be impaired.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects although not everybody gets them.</p><p>Get emergency medical help if you have signs of an allergic reaction (hives, difficult breathing, swelling in your face or throat) or a severe skin reaction(fever, sore throat, burning in your eyes, skin pain, red or purple skin rash that spreads and causes blistering and peeling).</p><p>FLOXAG can cause serious side effects, including tendon problems, side effects on your nerves (which may cause permanent nerve damage), serious mood or behavior changes (after just one dose), or low blood sugar (which can lead to coma).</p><p><strong>Stop taking this medicine and call your doctor at once if you have:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood sugar--headache, hunger, sweating, irritability, dizziness, nausea, fast heart rate, or feeling anxious or shaky;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nerve symptoms in your hands, arms, legs, or feet--numbness, weakness, tingling, burning pain;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious mood or behavior changes--nervousness, confusion, agitation, paranoia, hallucinations, memory problems, trouble concentrating, thoughts of suicide; or</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signs of tendon rupture--sudden pain, swelling, bruising, tenderness, stiffness, movement problems, or a snapping or popping sound in any of your joints (rest the joint until you receive medical care or instructions).</p><p><strong>Also, stop using FLOXAG and call your doctor at once if you have:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe stomach pain, diarrhea that is watery or bloody;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fast or pounding heartbeats, fluttering in your chest, shortness of breath, and sudden dizziness (like you might pass out);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The first sign of any skin rash, no matter how mild;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle weakness, breathing problems;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; jaundice (yellowing of the skin or eyes);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A seizure (convulsions); or</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased pressure inside the skull--severe headaches, ringing in your ears, vision problems, pain behind your eyes.</p><p><strong>Common side effects may include:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea, vomiting, stomach pain, diarrhea;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash.</p><p>This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store above 30&deg;C</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the carton &amp; blister after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package in order to protect from moisture.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Active Substance</strong>:<strong>gemifloxacin</strong></p><p>Each Film-Coated Tablet of FLOXAG contains gemifloxacin mesylate equivalent to gemifloxacin 320 mg.</p><p><strong>Excipients: </strong></p><p>Avicel PH101&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Crospovidone NF</p><p>Croscarmellose Sodium type A</p><p>Sodium Lauryl Sulphate</p><p>Povidone 30</p><p>Ethanol Absolute</p><p>Avicel PH 102</p><p>Magnesium Stearate</p><p><strong>Coating</strong>:</p><p>Hydroxypropyle methylcellulose</p><p>Titanium dioxide pharma grade</p><p>Purified talc</p><p>Polyethylene glycol MW 6000</p><p>Purified water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                FLOXAG Film-Coated tablet : A white to off-white color, oblong shaped, biconvex, film-coated tablet, engraved with "517" on one side and breakline on the other side.
Each carton contains 5 or 7Film-Coated tabletsin Aluminum thin soft temper plain strips.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>SPIMACO</strong></p><p>&nbsp;</p><p>AlQassim pharmaceutical plant</p><p>Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                March 2019.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فلوكساج يحتوى على مادة جيميفلوكساسين كمادة فعالة وهو مضاد حيوي من مجموعة الفلوروكينولونات وهو يعمل على محاربة البكتيريا في الجسم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يستخدم فلوكساج لعلاج أنواع مختلفة من العدوى البكتيرية في الرئتين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المضادات الحيوية من مجموعة الفلوروكينولونات يمكن أن تسبب أعراضاً جانبية خطيرة. يجب استخدام فلوكساج فقط للعدوى التي لا يمكن معالجتها بمضاد حيوي أكثر أماناً.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أيضاً استخدام فلوكساج لأغراض غير مدرجة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يمكن أن يسبب فلوكساج أعراضاً جانبية خطيرة, بما في ذلك مشاكل الأوتار, أو تلف الأعصاب, أو تغيرات مزاجية أو سلوكية خطيرة, أو انخفاض نسبة السكر في الدم.</p><p dir="RTL">توقف عن تناول هذا الدواء واتصل بطبيبك المعالج على الفور إذا كنت تعاني من أعراض مثل: الصداع, أو الجوع, أو التوتر, والشعور بالقلق أو الرعشات, أو خدر, أو وخز, أو إحساس بألم شبيه بالحرق, أو ارتباك, أو إثارة, أو أرق, أو مشاكل في الذاكرة أو التركيز, أو أفكار الانتحار.</p><p dir="RTL">فلوكساج قد يسبب تورماً أو تمزقاً في الوتر. توقف عن تناول هذا الدواء واستشِر طبيبك المعالج في الحال إذا كنت تعاني من ألم مفاجئ أو تورم أو كدمات أو ألم أو تصلب أو مشاكل في الحركة في أي من مفاصلك.</p><p dir="RTL">يجب عليك عدم استخدام هذا الدواء إذا كان لديك حساسية من مادة جيميفلوكساسين أو أى من الفلوروكينولونات الأخرى (سيبروفلوكساسين, ليفوفلوكساسين, موكسيفلوكساسين, أوفلوكساسين, نورفلوكساسين, وغيرها).</p><p dir="RTL">قد يسبب فلوكساج تورماً أو تمزقاً في الوتر (الألياف التي تربط العظام بالعضلات في الجسم), خاصةً في وتر أخيل بالكعب. يمكن حدوث ذلك أثناء فترة العلاج أو خلال عدة أشهر بعد التوقف عن تناول فلوكساج. قد تزداد احتمالية تعرضك لمشاكل الأوتار<strong> </strong>إذا كنت تجاوزت 60 سنة من العمر<strong> </strong>أو إذا كنت تتناول دواء الستيرويد, أو إذا كنت قد أجريت عملية زرع كلية أو قلب أو رئة.</p><p dir="RTL">أخبر طبيبك المعالج إذا تعرضت لأى مما يلى:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بالأوتار, أو التهاب المفاصل أو مشاكل أخرى بالمفاصل,</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داء السكري,</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب في العضلات أو الأعصاب, مثل الوهن العضلي الشديد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام ضربات القلب أو اضطراب إيقاع القلب (خاصةً إذا كنت تتناول دواء لعلاجه),</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة كيو تي الطويلة فى رسم القلب (الخاص بك أو بأحد أفراد الأسرة),</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلة في ابتلاع الأقراص.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض الكبد أو الكلى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصرع أو غيره من اضطرابات أو نوبات.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات المغنيسيوم أو البوتاسيوم في الدم.</p><p dir="RTL">من غير المعروف ما إذا كان هذا الدواء سيؤذي الجنين. أخبرى طبيبك المعالج إذا كنتِ حاملاً.</p><p dir="RTL">يجب عليكِ عدم إرضاع طفلك طبيعياً أثناء استخدام فلوكساج.</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">لم يتم اعتماد فلوكساج للاستخدام من قبل أي شخص يقل عمره عن 18 عاماً.</p><p dir="RTL">لا تتناول أقراص فلوكساج مع منتجات الألبان مثل الحليب أو اللبن, أو مع العصير المدعم بالكالسيوم. قد تأكل أو تشرب هذه المنتجات كجزء من الوجبة العادية, ولكن لا تستخدمها بمفردها عند تناول فلوكساج. حيث قد تقلل من فعالية الدواء.</p><p dir="RTL">قد تسبب المضادات الحيوية إسهالاً والذي قد يكون علامة على وجود عدوى جديدة. إذا كان لديك إسهال مائي أو دموي, اتصل بطبيبك المعالج قبل استخدام دواء مضاد للإسهال.</p><p dir="RTL">فلوكساج قد يجعلك معرَّضاً لحروق الشمس بسهولة أكبر. تجنب آشعة الشمس أو النوم فى الشمس لصباغة الجلد باللون الداكن. ارﺗﺪِ ﻣﻼﺑﺲ واﻗﻴﺔ واﺳﺘﺨﺪم واﻗﻲ اﻟﺸﻤﺲ (برقم <strong>SPF 30</strong> أو أﻋﻠﻰ) ﻋﻨﺪﻣﺎ ﺗﻜﻮن ﻓﻲ اﻟﺨﺎرج. أخبر طبيبك المعالج إذا كان لديك حرق شديد, أو احمرار, أو حكة, أو طفح جلدي, أو تورم بعد التعرض للشمس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>فلوكساج والأدوية الأخرى</strong></p><p dir="RTL">بعض الأدوية قد تجعل فلوكساج أقل فعالية بكثير عندما تؤخذ في نفس الوقت. إذا كنت تتناول أياً من الأدوية التالية, قم بتناول جرعة فلوكساج قبل ساعتين أو بعد 3 ساعات من تناول الدواء الآخر:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الحموضة التي تحتوي على المغنيسيوم أو الألومنيوم, أو سوكرالفيت (وهو دواء لعلاج قرحة الجهاز الهضمى),</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مسحوق أو أقراص مضغ ديدانوسين,</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مكملات الفيتامينات أو المعادن التي تحتوي على الألومنيوم أو الحديد أو المغنيسيوم أو الزنك.</p><p dir="RTL">فلوكساج يمكن أن يسبب مشكلة خطيرة في القلب. قد تكون مخاطرك أعلى إذا كنت تستخدم أدوية أخرى معينة للعدوى, أو الربو, أو مشاكل القلب, أو ارتفاع ضغط الدم, أو الاكتئاب, أو الأمراض العقلية, أو السرطان, أو الملاريا, أو فيروس نقص المناعة البشرية.</p><p dir="RTL">أخبر طبيبك المعالج عن جميع الأدوية الأخرى التى تتناولها, خاصةً:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بروبنيسيد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مدرات البول أو &quot;أقراص الماء&quot;,</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإنسولين أو أى دواء لعلاج السكري عن طريق الفم (تحقق من نسبة السكر في الدم بانتظام),</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مسيلات الدم مثل وارفارين,أو كومادين,أو جانتوفين,</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الالتهاب غير الستيرويدية مثل أسبرين, أيبوبروفين, نابروكسين, سيلكوكسيب, ديكلوفيناك, إندوميثاسين, ميلوكسيكام, وغيرها,</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء ستيرويد مثل بريدنيزون,أو ميثيل بريدنيزولون, وغيرها.</p><p dir="RTL">هذه القائمة ليست كاملة. فقد تتفاعل أدوية أخرى مع فلوكساج, بما في ذلك الأدوية الوصفية بالإضافة إلى تلك التي تصرف بدون وصفة طبية والفيتامينات والمنتجات العشبية. لم يتم ذكر جميع التفاعلات الممكنة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">اتبع جميع التوجيهات المذكورة بوصفتك الطبية. قم باستخدام الدواء بالضبط وفقاً لتلك التوجيهات.</p><p dir="RTL">قم بتناول فلوكساج بالماء مع شرب سوائل إضافية للحفاظ على عمل الكلى بشكل صحيح أثناء تناول هذا الدواء.</p><p dir="RTL">تناول الدواء في نفس الوقت كل يوم, مع أو بدون الطعام.</p><p dir="RTL">قم بابتلاع القرص كاملاً مع تجنب مضغه.</p><p dir="RTL">استخدم هذا الدواء لفترة زمنية كاملة كما أشار الطبيب, حتى لو تحسنت الأعراض لديك بسرعة. حيث قد يؤدي تخطي الجرعات إلى زيادة خطر الإصابة بعدوى مقاومة للأدوية. لن يتعامل فلوكساج مع العدوى الفيروسية مثل الأنفلونزا أو نزلات البرد.</p><p dir="RTL"><strong>ماذا يحدث لو نسيت تناول الجرعة الخاصة بك؟</strong></p><p dir="RTL">قم بتناول الجرعة الخاصة بك من هذا الدواء في أقرب وقت ممكن, ولكن قم بتخطي الجرعة الفائتة إذا كان الوقت قد حان لتناول الجرعة التالية. لا تقم بتناول جرعتين في وقت واحد.</p><p dir="RTL"><strong>ماذا يحدث إذا تناولت جرعة زائدة؟</strong></p><p dir="RTL">إذا تناولت جرعة زائدة, توجه إلى قسم الطوارئ بأقرب مستشفى فى الحال.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">تجنب القيادة أو أي أنشطة خطيرة حتى تعرف مدى تأثير هذا الدواء عليك. فقد تنخفض ردود أفعالك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">فلوكساج مثل جميع الأدوية فقد يسبب أعراضاً جانبية حتى وإن لم تكن تحدث لكل من يتناول هذا الدواء.</p><p dir="RTL">احصل على مساعدة طبية طارئة إذا كانت لديك علامات تفاعل تحسسي (مثل الشرى أو صعوبة في التنفس أو تورم في وجهك أو حلقك) أو تفاعل حاد في الجلد (حمى, التهاب في الحلق, حرق في عينيك, ألم في الجلد, طفح جلدي أحمر أو أرجواني ينتشر ويسبب تقرحات و تقشير).</p><p dir="RTL">يمكن أن يسبب فلوكساج أعراضاً جانبية خطيرة, بما في ذلك مشاكل الأوتار والأعراض الجانبية على أعصابك (والتي قد تسبب تلفاً دائما للأعصاب) أو تغيرات مزاجية أو سلوكية خطيرة (بعد جرعة واحدة فقط) أو انخفاض نسبة السكر في الدم (والتي يمكن أن تؤدي إلى غيبوبة).</p><p dir="RTL">توقف عن تناول هذا الدواء واتصل بطبيبك المعالج في الحال إذا كان لديك أي مما يلي:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى السكر بالدم و الذي يتمثل في أعراض مثل صداع , جوع, &nbsp;تعرق, توتر, دوخة, غثيان, سرعة ضربات القلب, أو الشعور بالقلق أو الاهتزاز,</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض بالأعصاب في اليدين أو الذراعين أو الساقين أو القدمين مثل الخدر أو الضعف أو الوخز أو وجود ألم شبيه بالحرق.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات مزاجية أو سلوكية خطيرة مثل العصبية, الارتباك, الإثارة, الأرق, هلوسة, مشاكل بالذاكرة, مشكلة في التركيز, أفكار الانتحار.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات تمزق الأوتار مثل ألم مفاجئ أو تورم أو كدمات أو ألم أو تصلب أو مشاكل في الحركة أو صوت طقطقة في أي من مفاصلك (قم بتثبيت المفصل حتى تتلقى الرعاية الطبية أو التعليمات).</p><p dir="RTL">أيضاً, يجب التوقف عن تناول فلوكساج واستشارة الطبيب المعالج على الفور إذا كان لديك أي مما يلي:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم شديد في المعدة, إسهال مائي أو دموي,</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسارع في ضربات القلب, ورفرفة في الصدر, وضيق في التنفس, ودوخة مفاجئة (شبيهة بحالة ما قبل الإغماء),</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العلامة الأولى لأي طفح جلدي, مهما كانت خفيفة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف العضلات ومشاكل في التنفس.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اليرقان (اصفرارالجلد أو اصفرار بياض العينين),</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبة (تشنجات),</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الضغط داخل الجمجمة والتي تتمثل في أعراض مثل صداع شديد, رنين في أذنيك, مشاكل في الرؤية, ألم خلف عينيك.</p><p dir="RTL">قد تشمل الأعراض الجانبية الشائعة ما يلي:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان وقيء وآلام المعدة وإسهال,</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع الرأس,</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة,</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي.</p><p dir="RTL">هذه ليست قائمة كاملة تشمل كل الأعراض الجانبية فقد تحدث بعض الأعراض الجانبية الأخرى. تواصل مع طبيبك المعالج للمشورة بشأن الأعراض الجانبية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يحفظ في درجة حرارة أعلى من 30 درجة مئوية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ الدواء بعيداً عن متناول ونظر الأطفال.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستعمل هذا الدواء بعد انتهاء تاريخ الصلاحية المدون على العبوة. وتاريخ الانتهاء يشير إلى آخر يوم فى الشهر المذكور.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ هذا الدواء فى عبوته الأصلية لحمايته من الرطوبة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم التخلص من الأدوية في مياه المجاري أو قمامة المنزل. اسأل الصيدلي كيف تتخلص من الأدوية التي لم تعد بحاجتها. لأن هذه الاعتبارات ستعمل على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هى جيميفلوكساسين.</p><p dir="RTL">يحتوى كل قرص مغلف بطبقة رقيقة من فلوكساج على جيميفلوكساسين ميسيلات يكافئ 320 ملجم من مادة جيميفلوكساسين.</p><p dir="RTL">مكونات أخرى وهى:</p><p dir="RTL">أفيسيل PH 101,</p><p dir="RTL">كروسبوفيدون NF,</p><p dir="RTL">كروسكارميللوز صوديوم نوع A,</p><p dir="RTL">صوديوم لوريل سلفات,</p><p dir="RTL">بوفيدون 30,</p><p dir="RTL">إيثانول مطلق</p><p dir="RTL">أفيسيل PH 102</p><p dir="RTL">إستيارات مغنيسيوم.</p><p dir="RTL"><strong>غلاف القرص</strong></p><p dir="RTL">هيدروكسى بروبيل ميثيل سيليولوز</p><p dir="RTL">ثانى أكسيد التيتانيوم درجة فارما</p><p dir="RTL">تالك منقى</p><p dir="RTL">بولى إيثيلين جليكول &nbsp;MW 6000</p><p dir="RTL">ماء منقى</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">فلوكساج أقراص مغلفة بطبقة رقيقة: هي أقراص مستطيلة لونها أبيض إلى أبيض فاتح, ثنائية التحدب, مغلفة بطبقة رقيقة, محفور عليها رقم &quot;517&quot; من جهة وخط فاصل للكسر من الجانب الآخر.</p><p dir="RTL">تحتوى كل عبوة من فلوكساج على 5 أو 7 أقراص مغلفة بطبقة رقيقة فى شرائط ألومنيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك الحقوق التسويقية و المصنع</p><p dir="RTL">الدوائية</p><p dir="RTL">مصنع الأدوية بالقصيم</p><p dir="RTL">الشركة السعودية للصناعات الدوائية والمستلزمات الطبية.</p><p dir="RTL">المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مارس 2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                FLOXAG®
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains gemifloxacin mesylate equivalent to gemifloxacin 320 mg.
For the full list of excipients, see section 6.1

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>FLOXAG is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (See&nbsp;DOSAGE AND ADMINISTRATION&nbsp;and&nbsp;Clinical Studies.)</p><p>Acute bacterial exacerbation of chronic bronchitis (ABECB)&nbsp;caused by&nbsp;<em>Streptococcus pneumoniae, Haemophilus influenzae</em>,&nbsp;<em>Haemophilusparainfluenzae,</em>&nbsp;or&nbsp;<em>Moraxella catarrhalis</em>.</p><p>Because fluoroquinolones, including FLOXAG, have been associated with serious adverse reactions (see&nbsp;WARNINGS) and for some patients ABECB is self-limiting, reserve FLOXAG for treatment of ABECB in patients who have no alternative treatment options.</p><p>Community-acquired pneumonia&nbsp;(of mild to moderate severity) caused by&nbsp;<em>Streptococcus pneumoniae</em>&nbsp;(including multi-drug resistant strains [MDRSP])*,&nbsp;<em>Haemophilus influenzae, Moraxella catarrhalis, Mycoplasma pneumoniae, Chlamydia pneumoniae</em>, or&nbsp;<em>Klebsiella pneumoniae</em>.</p><p><em>*</em>MDRSP: multi-drug resistant&nbsp;<em>Streptococcus pneumoniae</em>, includes isolates previously known as PRSP (penicillin-resistant&nbsp;<em>Streptococcus pneumoniae)</em>, and are strains resistant to two or more of the following antibiotics: penicillin (MIC &ge;2 &micro;g/mL), 2nd generation cephalosporins (e.g., cefuroxime), macrolides, tetracyclines and trimethoprim/sulfamethoxazole.</p><p>&nbsp;To reduce the development of drug-resistant bacteria and maintain the effectiveness of FLOXAG and other&nbsp;antibacterial&nbsp;drugs, FLOXAG should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.&nbsp; When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.&nbsp; In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>DOSAGE AND ADMINISTRATION</p><p>FLOXAG can be taken with or without food and should be swallowed whole with a liberal amount of liquid.&nbsp; The recommended dose of FLOXAG is 320 mg daily, according to the following table (Table 4).</p><p>Table 4. Recommended Dosage Regimen of FLOXAG &nbsp;<br />The clinical decision regarding the use of a 5 day or 7 day regimen should be guided by results of the initial sputum culture.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>INDICATION</p></td><td><p>DOSE / DURATION</p></td></tr><tr><td><p>Acute bacterial exacerbation of chronic bronchitis</p></td><td><p>One 320 mg tablet daily for 5 days</p></td></tr><tr><td><p>Community-acquired pneumonia (of mild to moderate severity)</p></td><td>&nbsp;</td></tr><tr><td><p><em>due to known or suspected S. pneumoniae, H. influenzae, M. pneumoniae, or C. pneumoniae infection</em></p></td><td><p>One 320 mg tablet daily for 5 days</p></td></tr><tr><td><p><em>due to known or suspected MDRSP*, K. pneumoniae, or M. catarrhalis infection</em></p></td><td><p>One 320 mg tablet daily for 7 days</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>*MDRSP: multi-drug resistant&nbsp;<em>Streptococcus pneumoniae</em>, includes isolates previously known as PRSP (penicillin-resistant&nbsp;<em>Streptococcus pneumoniae)</em>, and are strains resistant to two or more of the following antibiotics: penicillin (MIC &ge;2 &micro;g/mL), 2nd generation cephalosporins (e.g., cefuroxime), macrolides, tetracyclines and trimethoprim/sulfamethoxazole.</p><p>The recommended dose and duration of FLOXAG should not be exceeded (see Table 2).</p><p>Use in Renally Impaired Patients</p><p>Dose adjustment in patients with creatinine clearance &gt;40 mL/min is not required. Modification of the dosage is recommended for patients with creatinine &nbsp;clearance ?40 mL/min.&nbsp;Table 5 provides dosage guidelines for use in patients with renal impairment.</p><p>Table 5. Recommended Doses for Patients with Renal Impairment</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Creatinine Clearance&nbsp; (mL/min)</p></td><td><p>Dose</p></td></tr><tr><td><p>&gt;40</p></td><td><p>See Usual Dosage</p></td></tr><tr><td><p>&ge; 40</p></td><td><p>160 mg every 24 hours</p></td></tr></tbody></table><p>Patients requiring routine&nbsp;hemodialysis&nbsp;or continuous ambulatory&nbsp;peritoneal dialysis&nbsp;(CAPD) should receive 160 mg every 24 hours.</p><p>When only the serum creatinine concentration is known, the following formula may be used to estimate creatinine clearance.</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p>Males:</p></td><td><p>(weight in kg) x (140 &ndash; age)</p></td></tr><tr><td><p>(72) x serum creatinine (mg/100 mL)</p></td></tr><tr><td><p>Females:</p></td><td><p>(0.85) x (above value)</p></td></tr></tbody></table><p>Use in Hepatically Impaired Patients</p><p>No dosage adjustment is recommended in patients with mild (Child-Pugh Class A), moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment.</p><p>Use in Elderly</p><p>No dosage adjustment is recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4.3 Contraindications
FLOXAG is contraindicated in patients with a history of hypersensitivity to gemifloxacin, fluoroquinolone antibiotic agents, or any of the product components.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>WARNINGS</p><p>Disabling and Potentially Irreversible Serious Adverse Reactions Including Tendinitis and Tendon Rupture, Peripheral Neuropathy, and Central Nervous System Effects</p><p>Fluoroquinolones, including FLOXAG have been associated with disabling and potentially irreversible serious adverse reactions from different body systems that can occur together in the same patient. Commonly seen adverse reactions include&nbsp;tendinitis,&nbsp;tendon&nbsp;rupture,&nbsp;arthralgia,&nbsp;myalgia,&nbsp;peripheral neuropathy, and&nbsp;central nervous system&nbsp;effects (hallucinations, anxiety, depression, insomnia, severe headaches, and confusion). These reactions can occur within hours to weeks after starting FLOXAG. Patients of any age or without pre-existing risk factors have experienced &nbsp;&nbsp;these adverse reactions (See WARNINGS,&nbsp;<em>Tendinitis and Tendon Rupture, Peripheral Neuropathy and Central Nervous System Effects)</em></p><p>Discontinue FLOXAG immediately at the first signs or symptoms of any serious adverse reaction.&nbsp; In addition, avoid the use of fluoroquinolones, including FLOXAG, in patients who have experienced any of these serious adverse reactions associated with fluoroquinolones.</p><p>Tendinitis and Tendon Rupture</p><p>Fluoroquinolones, including FLOXAG, have been associated with an increased risk of tendinitis and tendon rupture in all ages.&nbsp; This adverse reaction most frequently involves the&nbsp;Achilles tendon, and has also been reported with the&nbsp;rotator cuff&nbsp;(the&nbsp;shoulder), the hand, the&nbsp;biceps, the thumb, and other tendons. Tendinitis or tendon rupture can occur &nbsp;within hours or days after starting FLOXAG, or as long as several months after completion of therapy. Tendinitis and tendon rupture can occur bilaterally.</p><p>The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking&nbsp;corticosteroid&nbsp;drugs, and in patients with kidney, heart or lung transplants. Other factors, in addition to age and corticosteroid use, that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous &nbsp;tendon disorders such as&nbsp;rheumatoid arthritis. &nbsp;Tendinitis and tendon rupture have also occurred in patients taking fluoroquinolones who do not have the above risk factors. Discontinue FLOXAGif &nbsp;the patient experiences pain, swelling, inflammation or rupture of a tendon. Avoid fluoroquinolones, including FLOXAG, in patients who have a history of tendon disorders or have experienced &nbsp;tendinitis or tendon rupture. Patients should be advised to rest at the first sign of tendinitis or tendon rupture, and to contact their healthcare provider regarding changing to a non-quinolone &nbsp;antimicrobial drug.</p><p>Peripheral Neuropathy</p><p>Fluoroquinolones, including FLOXAG, have been associated with an increased risk of peripheral&nbsp;neuropathy. Cases of sensory or sensorimotor axonal polyneuropathy affecting small and/or large axons resulting in paresthesias, hypoesthesias, dysesthesias and weakness have been reported in patients receiving fluoroquinolones, including FLOXAG.&nbsp; Symptoms may occur soon after initiation of FLOXAG and may be irreversible in some patients. Discontinue FLOXAG immediately if the patient experiences symptoms of peripheral neuropathy, including pain, &nbsp;burning, tingling, numbness, and/or weakness or other alterations in sensations including light touch, pain, temperature, position&nbsp;sense, and vibratory sensation.</p><p>CNS Effects</p><p>Fluoroquinolones, including FLOXAG, have been associated with an increased risk of central nervous system (CNS) effects, including convulsions, increased intracranial pressure (including&nbsp;pseudotumor cerebri), and toxic&nbsp;psychosis. In clinical studies with FLOXAG, central nervous system (CNS) effects have been reported infrequently. As with other fluoroquinolones, &nbsp;&nbsp; &nbsp;FLOXAG should be used with caution in patients with CNS diseases such as&nbsp;epilepsy&nbsp;or patients predisposed to convulsions. &nbsp;CNS stimulation which may lead to tremors, restlessness, anxiety,&nbsp;lightheadedness, confusion, hallucinations, paranoia, depression, insomnia, and rarely suicidal thoughts or acts may also be caused by other fluoroquinolones.&nbsp; If these reactions occur in patients receiving FLOXAG, discontinue FLOXAG immediately and institute appropriate measures.</p><p>Exacerbation of Myasthenia Gravis</p><p>Fluoroquinolones, including FLOXAG, have&nbsp;neuromuscular&nbsp;blocking activity and may exacerbate muscle weakness in patients with&nbsp;myasthenia gravis. &nbsp;Postmarketing serious adverse reactions, including deaths and requirement for ventilatory support, have been associated with fluoroquinolone use in patients with myasthenia gravis.&nbsp; Avoid FLOXAG in patients with known history of myasthenia gravis.&nbsp; (See&nbsp;PATIENT INFORMATION&nbsp;and&nbsp;ADVERSE REACTIONS/Post-Marketing Adverse Reactions.)</p><p>THE SAFETY AND EFFECTIVENESS OF FLOXAG IN CHILDREN, ADOLESCENTS (LESS THAN 18 YEARS OF AGE), PREGNANT WOMEN, AND LACTATING WOMEN HAVE NOT BEEN ESTABLISHED.&nbsp; (See PRECAUTIONS: Pediatric Use, Pregnancy and Nursing Mothers subsections.) &nbsp;</p><p>QT Effects</p><p>Fluoroquinolones may prolong the QT interval in some patients. FLOXAG should be avoided in patients with a history of prolongation of the QTc interval, patients with uncorrected &nbsp;electrolyte&nbsp;disorders (hypokalemia&nbsp;or&nbsp;hypomagnesemia), and patients receiving Class IA (e.g., quinidine, procainamide) or Class III (e.g.,&nbsp;amiodarone,&nbsp;sotalol) antiarrhythmic agents.</p><p>&nbsp;Pharmacokinetic studies between gemifloxacin and drugs that prolong the QTc interval such as&nbsp;erythromycin, antipsychotics, and&nbsp;tricyclic antidepressantshave not been performed. &nbsp;FLOXAG should be used with caution when given concurrently with these drugs, as well as in patients with ongoing proarrhythmic conditions, such as clinically significant&nbsp;bradycardia&nbsp;or acute myocardial&nbsp;ischemia.&nbsp; No&nbsp;cardiovascular&nbsp;morbidity or mortality attributable to QTc prolongation occurred with FLOXAG treatment in over 8119 patients, including 707 patients concurrently receiving drugs known to prolong the QTc interval and 7 patients with hypokalemia.</p><p>The likelihood of QTc prolongation may increase with increasing dose of the drug; therefore, the recommended dose should not be exceeded especially in patients with renal or hepatic impairment where the Cmax and AUC are slightly higher.&nbsp; QTc prolongation may lead to an increased risk for&nbsp;ventricular arrhythmias&nbsp;including torsades de pointes. The maximal change in the QTc &nbsp;&nbsp;interval occurs approximately 5-10 hours following oral administration of gemifloxacin.</p><p>Hypersensitivity Reactions</p><p>Serious hypersensitivity and/or anaphylactic reactions have been reported in patients receiving fluoroquinolone therapy, including FLOXAG. Hypersensitivity reactions &nbsp;reported in patients receiving fluoroquinolone therapy have occasionally been fatal.&nbsp; These reactions may occur following the first dose.&nbsp; Some reactions have been accompanied by cardiovascular collapse,&nbsp;hypotension/shock,&nbsp;seizure, loss of consciousness, tingling,&nbsp;angioedema(including tongue,&nbsp;laryngeal, throat or facial edema/swelling),&nbsp;airway obstruction&nbsp;(including bronchospasm, shortness of breath and acute respiratory distress),&nbsp;dyspnea,&nbsp;urticaria, itching and other serious skin reactions.</p><p>FLOXAG should be discontinued immediately at the appearance of any sign of an immediate type I hypersensitivity skin rash or any other manifestation of a hypersensitivity reaction; the need for continued fluoroquinolone therapy should be evaluated.&nbsp; As with other drugs, serious acute hypersensitivity reactions may require treatment with&nbsp;epinephrine&nbsp;and other resuscitative measures, including oxygen, intravenous fluids,&nbsp;antihistamines, corticosteroids,&nbsp;pressor&nbsp;amines and airway management as clinically indicated. (See&nbsp;PRECAUTIONS&nbsp;and&nbsp;ADVERSE REACTIONS.) &nbsp;Other serious and sometimes fatal adverse reactions, some due to hypersensitivity and some due to uncertain&nbsp;etiology, have been reported rarely in patients receiving therapy with quinolones, including FLOXAG.&nbsp; These events may be severe and generally occur following the administration of multiple doses. Clinical manifestations may include one or more of the following:</p><ul><li>fever, rash or severe&nbsp;dermatologic&nbsp;reactions (e.g., toxic&nbsp;epidermal&nbsp;necrolysis,&nbsp;Stevens-Johnson Syndrome);</li><li>vasculitis; arthralgia; myalgia; serum sickness;</li><li>allergic pneumonitis;</li><li>interstitial&nbsp;nephritis; acute renal insufficiency or failure;</li><li>hepatitis;&nbsp;jaundice; acute hepatic&nbsp;necrosis&nbsp;or failure;</li><li>anemia, including&nbsp;hemolytic&nbsp;and aplastic;</li><li>thrombocytopenia, including&nbsp;thrombotic thrombocytopenic purpura;&nbsp;leukopenia&nbsp;agranulocytosis;&nbsp;pancytopenia; and/or other hematologic abnormalities.</li></ul><p>Discontinue FLOXAG immediately at the first appearance of a skin rash, jaundice, or any other sign of hypersensitivity and institute supportive measures (See&nbsp;PATIENT INFORMATION&nbsp;and&nbsp;ADVERSE REACTIONS).</p><p>Clostridium Difficile Associated Diarrhea</p><p><em>Clostridium difficile</em>&nbsp;associated diarrhea (CDAD) has been reported with use of nearly all&nbsp;antibacterial&nbsp;agents, including FLOXAG, and may range in severity from mild diarrhea to fatal&nbsp;colitis. Treatment with antibacterial agents alters the normal&nbsp;flora&nbsp;of the&nbsp;colon&nbsp;leading to overgrowth of &nbsp;&nbsp;&nbsp;<em>C. difficile</em>.</p><p><em>&nbsp;C. difficile</em>&nbsp;produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of &nbsp;<em>C. difficile</em>&nbsp;cause increased morbidity and mortality, as these infections can be&nbsp;refractory&nbsp;to&nbsp;antimicrobial&nbsp;therapy and may require&nbsp;colectomy.&nbsp; CDAD must be considered in all patients who present with diarrhea following&nbsp;antibiotic&nbsp;use.&nbsp; Careful&nbsp;medical history&nbsp;is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p><p>&nbsp;If CDAD is suspected or confirmed, ongoing antibiotic use not directed against&nbsp;<em>C. difficile</em>&nbsp;may need to be discontinued.&nbsp; Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of&nbsp;<em>C. difficile</em>, and surgical evaluation should be instituted as clinically indicated.</p><p>Precautions</p><p>General</p><p>Prescribing FLOXAG in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drugresistant bacteria.</p><p>Rash</p><p>In clinical studies, rash occurred more often with FLOXAG than with therapy with comparator agents (2.7% vs. 0.6%).&nbsp; Increasing incidence of rash was associated with younger age (especially below 40), female gender, use of hormone replacement therapy and longer durations of therapy (see Table 2). Urticarial reactions, some of which were not classified as rash, were more &nbsp;common in FLOXAG patients than in comparator patients (0.6% vs. 0.2%).&nbsp; FLOXAG should be discontinued in patients developing a rash or urticaria while on treatment.&nbsp; (See&nbsp;ADVERSE REACTIONS&nbsp;and&nbsp;Clinical Studies.)</p><p>Table 2. Rash Incidence in FLOXAG Treated Patients from the Clinical Studies Population* by Gender, Age, and Duration of Therapy</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td>&nbsp;</td><td colspan="4"><p>Duration of FLOXAG Therapy</p></td></tr><tr><td><p>Gender &amp; Age (yr) Category</p></td><td><p>5 days</p></td><td><p>7 days</p></td><td><p>10 days**</p></td><td><p>14 days**</p></td></tr><tr><td><p>Female &lt; 40</p></td><td><p>10/399 (2.5%)</p></td><td><p>49/407 (12.0%)</p></td><td><p>20/131 (15.3%)</p></td><td><p>7/31 (22.6%)</p></td></tr><tr><td><p>Female &ge; 40</p></td><td><p>30/1438 (2.1%)</p></td><td><p>34/887 (3.8%)</p></td><td><p>19/308 (6.2%)</p></td><td><p>10/126 (7.9%)</p></td></tr><tr><td><p>Male &lt; 40</p></td><td><p>6/356 (1.7%)</p></td><td><p>26/453 (5.7%)</p></td><td><p>7/74 (9.5%)</p></td><td><p>3/39 (7.7%)</p></td></tr><tr><td><p>Male &ge; 40</p></td><td><p>10/1503 (0.7%)</p></td><td><p>26/984 (2.6%)</p></td><td><p>9/345 (2.6%)</p></td><td><p>3/116 (2.6%)</p></td></tr><tr><td><p>Totals</p></td><td><p>56/3696 (1.5%)</p></td><td><p>135/2732 (4.9%)</p></td><td><p>55/858 (6.4%)</p></td><td><p>23/312 (7.4%)</p></td></tr></tbody></table><p>&nbsp;</p><p>*includes patients from studies of community-acquired&nbsp;pneumonia, acute bacterial exacerbation of&nbsp;chronic bronchitis, and other indications **exceeds the recommended duration of therapy (see&nbsp;DOSAGE AND ADMINISTRATION)</p><p>The most common form of rash associated with FLOXAG was described as maculopapular and mild to moderate in severity. Eighty percent of rashes resolved within 14 days. &nbsp;Approximately 10% of the rashes (0.5% of all patients) were described as of severe intensity and approximately 10% of those with rash were treated with systemic steroids.&nbsp; There were no documented cases in the clinical trials of more serious skin reactions known to be associated with significant morbidity or mortality.</p><p>Moderate to severe&nbsp;photosensitivity/phototoxicity reactions, the latter of which may manifest as exaggerated sunburn reactions (e.g., burning,&nbsp;erythema, exudation,&nbsp;vesicles, blistering, edema) involving areas exposed to light (typically the face, Varea of the neck, extensor surfaces of the forearms, dorsa of the hands), can be associated with use of quinolones after sun or UV light exposure. Therefore excessive exposure to these sources of light should be avoided. Drug therapy should be discontinued if phototoxicity occurs. (See &nbsp;&nbsp;ADVERSE REACTIONS&nbsp;and&nbsp;ADVERSE REACTIONS: Post-Marketing Adverse Reactions.)</p><p>Hepatic Effects</p><p>Liver enzyme elevations (increased ALT and/or AST) occurred at similar rates in patients receiving FLOXAG 320 mg daily relative to comparator antimicrobial agents (ciprofloxacin,&nbsp;levofloxacin,&nbsp;clarithromycin/cefuroxime axetil,&nbsp;amoxicillin/clavulanate&nbsp;potassium, and&nbsp;ofloxacin).&nbsp; In patients who received gemifloxacin at doses of 480 mg per day or greater there was an increased incidence of elevations in liver enzymes.&nbsp; (See&nbsp;ADVERSE REACTIONS.)</p><p>There were no clinical symptoms associated with these liver enzyme elevations.&nbsp; The liver enzyme elevations resolved following cessation of therapy.&nbsp; The recommended dose of FLOXAG 320 mg daily should not be exceeded and the recommended length of therapy should not be exceeded.&nbsp; (See&nbsp;DOSAGE AND ADMINISTRATION.)</p><p>Renal Effects</p><p>Alteration of the dosage regimen is necessary for patientswith impairment of renal function (creatinine clearance ?40 mL/min). (See&nbsp;DOSAGE AND ADMINISTRATION.) Adequate hydration of patients receiving FLOXAG should be maintained to prevent the formation of a highly concentrated urine.</p><p>Information for Patients</p><p>Advise the patient to read the FDA-approved patient labeling (Medication Guide)</p><p>Serious Adverse Reactions</p><p>Advise patients to stop taking FLOXAG if they experience an adverse reaction and to call their healthcare provider for advice on completing the full course of treatment with another antibacterial drug.</p><p>Inform patients of the following serious adverse reactions that have been associated with FLOXAG or other fluoroquinolone use:</p><ul><li>Disabling and potentially irreversible serious adverse reactions that may occur together, including tendinitis and tendon rupture, peripheral neuropathies, and central nervous system effects, have been associated with use of FLOXAG and may occur together in the same patient. Inform patients to stop taking FLOXAG immediately if they experience an adverse reaction and to call their healthcare provider;</li><li>Tendinitis and tendon rupture: instruct patients to contact their healthcare provider if they experience pain, swelling, or inflammation of a tendon, or weakness or inability to use one of their joints; rest and refrain from exercise; and discontinue FLOXAG treatment. The risk of severe tendon disorders with fluoroquinolones is higher in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants;</li><li>Peripheral neuropathies: Inform patients that peripheral neuropathies have been associated with the use of FLOXAG, that symptoms may occur soon after initiation of therapy and may be irreversible.&nbsp; If symptoms of peripheral neuropathy including pain, burning, tingling, numbness and/or weakness develop, patients should immediately discontinue FLOXAG and contact their physician;</li><li>Central nervous system effects (for example, convulsions, dizziness, lightheadedness, increased intracranial pressure): Inform patients that convulsions have been reported in patients receiving fluoroquinolones, including FLOXAG.&nbsp; Patients should notify their physician before taking FLOXAG if they have a history of convulsions, seizures, or epilepsy; Inform patients that other central nervous system problems such as tremors, restlessness, lightheadedness, confusion and hallucinations may occur rarely; &nbsp;&nbsp;</li><li>Exacerbation of Myasthenia Gravis: Inform patients that fluoroquinolones like FLOXAG may cause worsening of myasthenia gravis symptoms, including muscle weakness and breathing problems. Patients should call their healthcare provider right away if they have any worsening muscle weakness or breathing problems; &nbsp;</li><li>Hypersensitivity Reactions: Inform patients that FLOXAG may be associated with hypersensitivity reactions, including anaphylactic reactions, even following a single dose; patients should immediately discontinue the drug at the sign of a rash or other allergic reaction and seek medical care; Inform patients that FLOXAG has been associated with rash and hives.&nbsp; Rash occurs more commonly in those under 40, especially women and in women on hormone replacement therapy.&nbsp; The incidence of rash increases with duration more than 5 days and particularly longer than 7 days.&nbsp; Patients should discontinue FLOXAG and call their healthcare provider if they develop a rash;</li><li>Diarrhea: Inform patients that diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued.&nbsp; Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without&nbsp;stomach cramps&nbsp;and fever) even as late as two or more months after having taken the last dose of the antibiotic.&nbsp; If this occurs, patients should contact their physician as soon as possible;</li><li>Prolongation of the QT interval: inform patients of the following:</li><li>that FLOXAG may cause changes in the&nbsp;electrocardiogram&nbsp;(QTc interval prolongation); &nbsp;</li><li>that FLOXAG should be avoided in patients receiving Class IA (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic agents; &nbsp;</li><li>that FLOXAG should be used with caution in patients receiving drugs that affect the QTc interval such as cisapride, erythromycin, antipsychotics, and tricyclic&nbsp;antidepressants; &nbsp;</li><li>to inform their physician of any personal or family history of QTc prolongation or proarrhythmic conditions such as hypokalemia, bradycardia, or recent myocardial ischemia; &nbsp;</li><li>to contact their physician if they experience&nbsp;palpitations&nbsp;or&nbsp;fainting&nbsp;spells while taking FLOXAG; &nbsp;</li><li>that FLOXAG may cause dizziness; if this occurs, patients should not operate an automobile or machinery or engage in activities requiring mental alertness or coordination;</li><li>Photosensitivity/Phototoxicity: Inform patients that photosensitivity/phototoxicity has been reported in patients receiving quinolones.&nbsp; Patients should minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment) while taking quinolones.&nbsp; If patients need to be outdoors while using quinolones, they should wear loose-fitting clothes that protect skin from sun exposure and discuss other sun protection measures with their physician.&nbsp; If a sunburn-like reaction or skin eruption occurs, patients should contact their physician;</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>DRUG INTERACTIONS</p><p>Administration of repeat doses of FLOXAG had no effect on the repeat dose pharmacokinetics of&nbsp;theophylline,&nbsp;digoxin&nbsp;or an ethinylestradiol/levonorgestrol oral contraceptive product in healthy subjects.&nbsp; (See&nbsp;CLINICAL PHARMACOLOGY: Drug-Drug Interactions.)</p><p>Concomitant administration of FLOXAG and&nbsp;calcium carbonate,&nbsp;cimetidine,&nbsp;omeprazole, or an&nbsp;estrogen/progesterone&nbsp;oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.&nbsp; (See&nbsp;CLINICAL PHARMACOLOGY.)</p><p>Concomitant administration of FLOXAG with probenecid resulted in a 45% increase in systemic exposure to gemifloxacin.&nbsp; (See&nbsp;CLINICAL PHARMACOLOGY.)</p><p>FLOXAG had no significant effect on the&nbsp;anticoagulant&nbsp;effect of warfarin in healthy subjects on stable warfarin therapy.&nbsp; However, post-marketing reports of increases in the INR, or PT, and/or clinical episodes of bleeding in patients have been noted with the use of quinolones, including FLOXAG, and warfarin, or its derivatives.&nbsp; In addition, infectious disease and its accompanying inflammatory process, age and general status of the patient are risk factors for increased anticoagulation activity.&nbsp; Therefore, the PT, INR or other suitable&nbsp;coagulation&nbsp;test should be closely monitored if a quinolone&nbsp;antimicrobial, including FLOXAG, is administered concomitantly with warfarin or its derivatives.</p><p>Quinolones form chelates with alkaline earth and transition metals.&nbsp; The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium. Magnesium-and/or aluminum-containing&nbsp;antacids, products containing&nbsp;ferrous sulfate(iron), multivitamin preparations containing&nbsp;zinc&nbsp;or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FLOXAG.&nbsp;&nbsp;Sucralfate&nbsp;should not be taken within 2 hours of FLOXAG. (See &nbsp;CLINICAL PHARMACOLOGY.)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p>Teratogenic Effects</p><p>Pregnancy Category C. Gemifloxacin treatment during organogenesis caused fetal growth retardation in mice (oral dosing at 450 mg/kg/day), rats (oral dosing at 600 mg/kg/day) and rabbits (IV dosing at 40 mg/kg/day) at AUC levels which were 2-, 4- and 3-fold those in women given oral doses of 320 mg.&nbsp; In rats, this growth retardation appeared to be reversible in a pre- and postnatal development study (mice and rabbits were not studied for the reversibility of this effect).&nbsp; Treatment of pregnant rats at 8-fold clinical exposure (based upon AUC&nbsp; comparisons) caused fetal brain and ocular malformations in the presence of maternal toxicity.&nbsp; The overall no-effect exposure level in pregnant animals was approximately 0.8 to 3-fold clinical exposure.</p><p>The safety of FLOXAG in pregnant women has not been established. FLOXAG should not be used in pregnant women unless the potential benefit to the mother outweighs the risk to&nbsp; the fetus. There are no adequate and well-controlled studies in pregnant women.</p><p>Nursing Mothers</p><p>Gemifloxacin is excreted in the breast milk of rats. There is no information on excretion of gemifloxacin into human milk.&nbsp;&nbsp; Therefore, FLOXAG should not be used in lactating women unless the potential benefit to the mother outweighs the risk.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>FLOXAG can make you feel dizzy and lightheaded. Do not drive, operate machinery, or do other activities that require mental alertness or coordination until you know how FLOXAG affects you.<strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>SIDE EFFECTS</p><p>In clinical studies, 8119 patients received daily oral doses of 320 mg FLOXAG.&nbsp; In addition, 1797 healthy volunteers and 81 patients with renal or hepatic impairment received single or repeat doses of gemifloxacin in clinical&nbsp;pharmacology&nbsp;studies.&nbsp; The majority of adverse reactions experienced by patients in clinical trials were considered to be of mild to moderate severity.</p><p>FLOXAG was discontinued because of an adverse event (determined by the investigator to be possibly or probably related to drug) in 2.0% of patients, primarily due to rash (0.8%), nausea (0.3%), diarrhea (0.3%),&nbsp;urticaria&nbsp;(0.2%) and vomiting (0.2%).&nbsp; Comparator antibiotics were discontinued because of an adverse event at an overall comparable rate of 2.1%, primarily due to diarrhea (0.5%), nausea (0.4%), vomiting (0.3%), rash (0.3%), abdominal pain (0.2%) and&nbsp;vertigo&nbsp;(0.2%). The mostcommonly reported adverse events with a frequency of ?2% forpatients receiving 320 mg FLOXAG versus comparator drug (beta-lactam antibiotics, macrolides or other fluoroquinolones) are as follows: diarrhea 5.0% vs. 6.2%; rash 3.5% vs. 1.1%; nausea 3.7% vs. 4.5%; headache 4.2% vs. 5.2%; abdominal pain 2.2% vs. 2.2%; vomiting 1.6% vs. 2.0%; and dizziness 1.7% vs. 2.6%. &nbsp;</p><p>Adverse Events with a Frequency of Less than 1%</p><p>Additional drug-related adverse events (possibly or probablyrelated) in the 8119 patients, with a frequency of &gt;0.1% to ?1% included: abdominal pain,&nbsp;anorexia, constipation,&nbsp;dermatitis, dizziness,&nbsp;dry mouth,&nbsp;dyspepsia, fatigue,&nbsp;flatulence, fungal infection,&nbsp;gastritis,&nbsp;genital&nbsp;moniliasis, genital&nbsp;pruritus,&nbsp;hyperglycemia, increased alkaline phosphatase, increased ALT, increased AST, increased&nbsp;creatine&nbsp;phosphokinase, insomnia,&nbsp;leukopenia, pruritus,&nbsp;somnolence, taste perversion,&nbsp;thrombocythemia, urticaria,&nbsp;vaginitis, and vomiting.</p><p>Other adverse events reported from clinical trials which have potential clinical significance and which were considered to have a suspected relationship to the drug, that occurred in ?0.1% of patients were: abnormal urine, abnormal vision,&nbsp;anemia,&nbsp;arthralgia,&nbsp;asthenia,&nbsp;back pain, bilirubinemia,&nbsp;dyspnea,&nbsp;eczema,&nbsp;eosinophilia, facial edema, flushing,&nbsp;gastroenteritis,&nbsp;granulocytopenia,&nbsp;hot flashes, increased GGT, increased non-protein&nbsp;nitrogen, leg cramps, moniliasis,&nbsp;myalgia, nervousness, non-specified&nbsp;gastrointestinal&nbsp;disorder, pain,&nbsp;pharyngitis,&nbsp;photosensitivity/phototoxicity reactions,&nbsp;pneumonia,&nbsp;thrombocytopenia,&nbsp;tremor, vertigo. (See&nbsp;PRECAUTIONS.)</p><p>In clinical trials of acute bacterial exacerbation of&nbsp;chronic bronchitis&nbsp;(ABECB) and community&nbsp;acquired&nbsp;pneumonia (CAP), the incidences of rash were as follows (Table 3):</p><p>Table 3. Incidence of Rash by Clinical Indication in Patients Treated with FLOXAG</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2">&nbsp;</td><td colspan="2"><p>ABECB (5 days)&nbsp;<br />N = 2284</p></td><td colspan="2"><p>CAP (5 days)&nbsp;<br />N = 256</p></td><td colspan="2"><p>CAP (7 days)&nbsp;<br />N = 643</p></td></tr><tr><td><p>n/N</p></td><td><p>%</p></td><td><p>n/N</p></td><td><p>%</p></td><td><p>n/N</p></td><td><p>%</p></td></tr><tr><td><p>Totals</p></td><td><p>27/2284</p></td><td><p>1.2</p></td><td><p>1/256</p></td><td><p>0.4</p></td><td><p>26/643</p></td><td><p>4.0</p></td></tr><tr><td><p>Females, &lt; 40 years</p></td><td><p>NA*</p></td><td>&nbsp;</td><td><p>1/37</p></td><td><p>2.7</p></td><td><p>8/88</p></td><td><p>9.1</p></td></tr><tr><td><p>Females, &ge; 40 years</p></td><td><p>16/1040</p></td><td><p>1.5</p></td><td><p>0/73</p></td><td><p>0</p></td><td><p>5/214</p></td><td><p>2.3</p></td></tr><tr><td><p>Males, &lt; 40 years</p></td><td><p>NA*</p></td><td>&nbsp;</td><td><p>0/65</p></td><td><p>0</p></td><td><p>5/101</p></td><td><p>5.0</p></td></tr><tr><td><p>Males,&ge; &nbsp;40 years</p></td><td><p>11/1203</p></td><td><p>0.9</p></td><td><p>0/81</p></td><td><p>0</p></td><td><p>8/240</p></td><td><p>3.3</p></td></tr></tbody></table><p>&nbsp;</p><p>* insufficient number of patients in this category for a meaningful analysis (See&nbsp;PRECAUTIONS).</p><p>Laboratory Changes</p><p>The percentages of patients who received multiple doses of FLOXAG and had a laboratory abnormality are listed below. It is not known whether these abnormalities were &nbsp;related to FLOXAG or an underlying condition.</p><p><em>Clinical Chemistry</em>: increased ALT (1.7%), increased AST (1.3%), increased creatine phosphokinase (0.7%), increased alkaline phosphatase (0.4%), increased total bilirubin (0.4%), increased&nbsp;potassium&nbsp;(0.3%), decreased sodium (0.2%), increased&nbsp;blood urea nitrogen&nbsp;(0.3%), decreased&nbsp;albumin&nbsp;(0.3%), increased serum creatinine (0.2%), decreased calcium (0.1%), decreased total protein (0.1%), decreased potassium (0.1%), increased sodium (0.1%), increased&nbsp;lactate dehydrogenase&nbsp;(&lt;0.1%) and increased calcium (&lt;0.1%).</p><p><em>CPK elevations were noted infrequently</em>: 0.7% in FLOXAG patients vs. 0.7% in the comparator patients.</p><p><em>Hematology</em>: increased platelets (1.0%), decreased neutrophils (0.5%), increased neutrophils (0.5%), decreased&nbsp;hematocrit&nbsp;(0.3%), decreased&nbsp;hemoglobin(0.2%), decreased platelets (0.2%), decreased&nbsp;red blood cells&nbsp;(0.1%), increased hematocrit (0.1%), increased hemoglobin (0.1%), and increased red blood cells (0.1%).</p><p>In clinical studies, approximately 7% of the FLOXAG treated patients had elevated ALT values immediately prior to entry into the study. Of these patients, approximately 15% showed a &nbsp;further elevation of their ALT at the on-therapy visit and 9% showed a further elevation at the end of therapy visit.&nbsp; None of these patients demonstrated evidence of hepatocellular&nbsp;jaundice.&nbsp; For the pooled comparators, approximately 6% of patients had elevated ALT values immediately prior to entry into the study.&nbsp; Of these patients, approximately 7% showed a further elevation of their ALT at the on-therapy visit and 4% showed a further elevation at the end of therapy visit.</p><p>In a clinical trial where 638 patients received either a single 640 mg dose of gemifloxacin or 250 mg&nbsp;BID&nbsp;of&nbsp;ciprofloxacin&nbsp;for 3 days, there was an increased incidence of ALT elevations in the gemifloxacin arm (3.9%) vs. the comparator arm (1.0%).&nbsp; In this study, two patients experienced ALT elevations of 8 to 10 times the upper limit of normal.&nbsp; These elevations were&nbsp;asymptomatic&nbsp;and reversible.</p><p>Post-Marketing Adverse Reactions</p><p>The majority of the post-marketing adverse events reported were&nbsp;cutaneous&nbsp;and most of these were rash. Some of these cutaneous adverse events were &nbsp;considered serious.&nbsp; The majority of the rashes occurred in women and in patients under 40 years of age.</p><p>The following are additional adverse reactions reported during the post-marketing use of FLOXAG. Since these reactions are reported voluntarily from a population of uncertain size, it is impossible to reliably estimate their frequency or establish a causal relationship to FLOXAG exposure:</p><ul><li>Peripheral neuropathy&nbsp;that may be irreversible;</li><li>Anaphylactic reaction,&nbsp;erythema multiforme, skin exfoliation, facial swelling;</li><li>Exacerbation of&nbsp;myasthenia gravis;</li><li>Hemorrhage, increased&nbsp;international normalized ratio&nbsp;(INR), retinal hemorrhage;</li><li>Peripheral edema;</li><li>Renal failure;</li><li>Prolonged QT,&nbsp;supraventricular tachycardia,&nbsp;syncope,&nbsp;transient ischemic attack;</li><li>Photosensitivity/phototoxicity reaction (See&nbsp;PRECAUTIONS.);</li><li>Antibiotic-associated&nbsp;colitis; &nbsp;</li><li>Tendon&nbsp;rupture.<table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p> The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p>o Reporting hotline: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p></td></tr></tbody></table></li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any signs or symptoms of overdosage should be treated symptomatically.&nbsp; No specific antidote is known.&nbsp; In the event of acute oral overdosage, the stomach should be emptied by inducing vomiting or by gastric lavage; the patient should be carefully observed and treated symptomatically with appropriate hydration maintained.&nbsp; Hemodialysis removes approximately 20 to 30% of an oral dose of gemifloxacin from plasma.</p><p>Mortality occurred at oral gemifloxacin doses of 1600 mg/kg in rats and 320 mg/kg in mice. The minimum lethal intravenous doses in these species were 160 and 80 mg/kg, respectively.&nbsp; Toxic signs after administration of a single high oral dose (400 mg/kg) of gemifloxacin to rodents included ataxia, lethargy, piloerection, tremor, and clonic convulsions.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Microbiology</p><p>Gemifloxacin has&nbsp;in vitro&nbsp;activity against a wide range of&nbsp;Gram-negative and&nbsp;Gram-positive&nbsp;microorganisms.&nbsp; Gemifloxacin is bactericidal with minimum bactericidal concentrations (MBCs) generally within one dilution of the minimum inhibitory concentrations (MICs).&nbsp; Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and&nbsp;topoisomerase&nbsp;IV (TOPO IV), which are&nbsp;essential&nbsp;for bacterial growth. &nbsp;Streptococcus pneumoniaeshowing mutations in both DNA gyrase and TOPO IV (double mutants) are resistant to most fluoroquinolones.&nbsp; Gemifloxacin has the ability to inhibit both enzyme systems at therapeutically relevant drug levels in&nbsp;S. pneumoniae&nbsp;(dual targeting), and has MIC values that are still in the susceptible range for some of these double mutants.&nbsp; However, the presence of double mutants was not evaluated in clinical trials; therefore, the clinical significance of these&nbsp;in vitrodata are unknown.</p><p>The mechanism of action of quinolones, including gemifloxacin, is different from that of macrolides, beta-lactams, aminoglycosides, or tetracyclines; therefore, microorganisms resistant to these classes of drugs may be susceptible to gemifloxacin and other quinolones.&nbsp; There is no known cross-resistance between gemifloxacin and the above mentioned classes of antimicrobials.</p><p>The main mechanism of fluoroquinolone resistance is due to mutations in DNA gyrase and/or TOPO IV.&nbsp; Resistance to gemifloxacin develops slowly via multistep mutations and efflux in a manner similar to other fluoroquinolones.&nbsp; The frequency of spontaneous mutation is low (10-7 to &lt;10-10). Although cross-resistance has been observed between gemifloxacin and other fluoroquinolones, some microorganisms resistant to other fluoroquinolones may be susceptible to gemifloxacin.</p><p>Gemifloxacin has been shown to be active against most strains of the following microorganisms, both&nbsp;in vitro&nbsp;and in clinical infections as described in the&nbsp;INDICATIONS AND USAGE&nbsp;section.</p><p>Aerobic Gram-Positive Microorganisms</p><p>Streptococcus pneumoniae&nbsp;(including multi-drug resistant strains [MDRSP])*</p><p>*MDRSP: multi-drug resistant&nbsp;Streptococcus pneumoniae, includes isolates previously known as PRSP (penicillin-resistant&nbsp;Streptococcus pneumoniae), and are strains resistant to two or more of the following antibiotics: penicillin (MIC &ge;2 &micro;g/mL), 2nd generation cephalosporins (e.g., cefuroxime), macrolides, tetracyclines and&nbsp;trimethoprim/sulfamethoxazole.</p><p>Aerobic Gram-Negative Microorganisms</p><p>Haemophilus influenzae<br />Haemophilusparainfluenzae<br />Klebsiella pneumoniae&nbsp;(many strains are only moderately susceptible)&nbsp;Moraxella catarrhalis</p><p>Other Microorganisms</p><p>Chlamydia pneumoniae<br />Mycoplasma pneumoniae</p><p>The following data are available,&nbsp;but their clinical significance is unknown.</p><p>Gemifloxacin exhibits&nbsp;in vitro&nbsp;minimal inhibitory concentrations (MICs) of 0.25 &micro;g/mL or less against most (?90%)strains of the following microorganisms; however, the safety and effectiveness of gemifloxacin in treating clinical infections due to these microorganisms has not been established in adequate and well-controlled clinical trials:</p><p>Aerobic Gram-Positive Microorganisms</p><p>Staphylococcus aureus&nbsp;(methicillin-susceptible strains only)<br />Streptococcus pyogenes</p><p>Aerobic Gram-Negative Microorganisms</p><p>Acinetobacter lwoffii<br />Klebsiellaoxytoca<br />Legionella pneumophila<br />Proteus vulgaris</p><p>Susceptibility Tests</p><p>Dilution techniques</p><p>Quantitative&nbsp;methods are used to determine&nbsp;antimicrobial&nbsp;minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to &nbsp;antimicrobial compounds.&nbsp; The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method 1 (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of gemifloxacin powder.&nbsp; The MICs should be interpreted according to the following criteria:</p><p>For testing&nbsp;Klebsiella pneumoniae:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>MIC (&micro;g/mL)</p></td><td><p>Interpretation</p></td></tr><tr><td><p>&le;0.25</p></td><td><p>Susceptible (S)</p></td></tr><tr><td><p>0.5</p></td><td><p>Intermediate (I)</p></td></tr><tr><td><p>&ge;1.0</p></td><td><p>Resistant (R)</p></td></tr></tbody></table><p>&nbsp;</p><p>For testing&nbsp;Haemophilus influenzae&nbsp;and&nbsp;Haemophilusparainfluenzaea:&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>MIC (&micro;g/mL)</p></td><td><p>Interpretation</p></td></tr><tr><td><p>&le;0.12</p></td><td><p>Susceptible (S)</p></td></tr></tbody></table><p>aThis interpretive standard is applicable only to broth microdilution susceptibility testing with&nbsp;Haemophilus influenzae&nbsp;and&nbsp;Haemophilusparainfluenzae&nbsp;using&nbsp;Haemophilus&nbsp;Test Medium (HTM)1.</p><p>The current absence of data on resistant strains precludes defining any results other than susceptible.&nbsp; Strains yielding MIC results suggestive of a nonsusceptiblecategory should be submitted to a reference laboratory for further testing. &nbsp;</p><p>For testing&nbsp;Streptococcus pneumoniae:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>MIC (&micro;g/mL)</p></td><td><p>Interpretation</p></td></tr><tr><td><p>&le;0.12</p></td><td><p>Susceptible (S)</p></td></tr><tr><td><p>0.25</p></td><td><p>Intermediate (I)</p></td></tr><tr><td><p>&ge;0.5</p></td><td><p>Resistant (R)</p></td></tr></tbody></table><p>bThese interpretive standards are applicable only to broth microdilution susceptibility tests using cation-adjusted Mueller-Hinton broth with 2-5% lysed horse blood.</p><p>A report of Susceptibleindicates that the&nbsp;pathogen&nbsp;is likely to be inhibited if the antimicrobial compound in the blood reaches the concentration usually achievable.&nbsp; A report of Intermediateindicates that the result should be considered equivocal, and if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated.&nbsp; This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used.&nbsp; This category also provides a buffer zone, which prevents small uncontrolled technical factors from causing major discrepancies in interpretation.&nbsp; A report of Resistantindicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentration usually achievable; other therapy should be selected.</p><p>Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures.&nbsp; Standard gemifloxacin powder should provide the following MIC values:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Microorganism</p></td><td><p>&nbsp;</p></td><td><p>MIC Range (&micro;g/mL)</p></td></tr><tr><td><p><em>Escherichia coli</em></p></td><td><p>ATCC 25922</p></td><td><p>0.004-0.016</p></td></tr><tr><td><p><em>Haemophilus influenzae</em></p></td><td><p>ATCC 49247</p></td><td><p>0.002-0.008<sup>c</sup></p></td></tr><tr><td><p><em>Streptococcus pneumoniae</em></p></td><td><p>ATCC 49619</p></td><td><p>0.008-0.03<sup>d</sup></p></td></tr></tbody></table><p>&nbsp;</p><p>cThis quality control range is applicable to only&nbsp;H. influenzae&nbsp;ATCC 49247 tested by a broth microdilution procedure using&nbsp;Haemophilus&nbsp;Test Medium (HTM)1.<br />dThis quality control range is applicable to only&nbsp;S. pneumoniae&nbsp;ATCC 49619 tested by a broth microdilution procedure using cation-adjusted Mueller-Hinton broth with 2-5% lysed horse blood.</p><p>Diffusion Techniques</p><p>Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds.&nbsp; One such standardized procedure2 requires the use of standardized inoculum concentrations.&nbsp; This procedure uses paper disks impregnated with 5 &micro;g gemifloxacin to test the susceptibility of microorganisms to gemifloxacin.</p><p>Reports from the laboratory providing results of the standard single-disk susceptibility test with a 5 &micro;g gemifloxacin disk should be interpreted according to the following criteria:</p><p>For testing&nbsp;Klebsiella pneumoniae: &nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Zone Diameter (mm)</p></td><td><p>Interpretation</p></td></tr><tr><td><p>&le;20</p></td><td><p>Susceptible (S)</p></td></tr><tr><td><p>16-19</p></td><td><p>Intermediate (I)</p></td></tr><tr><td><p>&ge;15</p></td><td><p>Resistant (R)</p></td></tr></tbody></table><p>For testing&nbsp;Haemophilus influenzae&nbsp;and&nbsp;Haemophilusparainfluenzae:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Zone Diameter (mm)</p></td><td><p>Interpretation</p></td></tr><tr><td><p>&ge;18</p></td><td><p>Susceptible (S)</p></td></tr></tbody></table><p>This interpretive standard is applicable only to disk diffusion susceptibility testing with&nbsp;Haemophilus influenzae&nbsp;and&nbsp;Haemophilusparainfluenzae&nbsp;using&nbsp;Haemophilus&nbsp;Test Medium (HTM).2</p><p>The current absence of data on resistant strains precludes defining any results other than Susceptible.&nbsp; Strains yielding zone diameter results suggestive of a nonsusceptible category should be submitted to a reference laboratory for further testing.</p><p>For testing&nbsp;Streptococcus pneumoniae:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Zone Diameter (mm)</p></td><td><p>Interpretation</p></td></tr><tr><td><p>&ge;23</p></td><td><p>Susceptible (S)</p></td></tr><tr><td><p>20-22</p></td><td><p>Intermediate (I)</p></td></tr><tr><td><p>&le;19</p></td><td><p>Resistant (R)</p></td></tr></tbody></table><p><sup>f</sup>&nbsp;These zone diameter standards apply only to tests performed using Mueller-Hinton agar supplemented with 5% defibrinated sheep blood incubated in 5% CO2.</p><p>Interpretation should be as stated above for results using dilution techniques.&nbsp; Interpretation involves correlation of the diameter obtained in the disk test with the MIC for gemifloxacin.</p><p>As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures.&nbsp; For the diffusion technique, the 5 &micro;g gemifloxacin disk should provide the following zone diameters in these laboratory quality control strains:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Microorganism</p></td><td><p>&nbsp;</p></td><td><p>Zone Diameter (mm)</p></td></tr><tr><td><p><em>Escherichia coli</em></p></td><td><p>ATCC 25922</p></td><td><p>29-36</p></td></tr><tr><td><p><em>Haemophilus influenzae</em></p></td><td><p>ATCC 49247</p></td><td><p>30-37<sup>g</sup></p></td></tr><tr><td><p><em>Streptococcus pneumoniae</em></p></td><td><p>ATCC 49619</p></td><td><p>28-34<sup>h</sup></p></td></tr></tbody></table><p>This quality control range is applicable to only&nbsp;H. influenzae&nbsp;ATCC 49247 tested by a disk diffusion procedure using&nbsp;Haemophilus&nbsp;Test Medium (HTM)2.<br />hThis quality control range is applicable to only&nbsp;S. pneumoniae&nbsp;ATCC 49619 tested by a disk diffusion procedure using Mueller-Hinton agar supplemented with 5% defibrinated sheep blood and incubated in 5% CO2.</p><p>Clinical Studies</p><p>Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB)</p><p>FLOXAG (320 mg once daily for 5 days) was evaluated for the treatment of acute bacterial exacerbation of&nbsp;chronic bronchitis&nbsp;in three pivotal double-blind, randomized, actively-controlled clinical trials (studies 068, 070, and 212). The primary efficacy parameter in these studies was the clinical response at follow-up (day 13 to 24). The results of the clinical response at follow-up for the &nbsp; &nbsp;principal ABECB studies demonstrate that FLOXAG 320 mg PO once daily for 5 days was at least as good as the comparators given for 7 days.&nbsp; The results are shown in Table 6 below.</p><p>Table 6. Clinical Response at Follow-Up (Test of Cure): Pivotal ABECB Studies</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Drug Regimen</p></td><td><p>Success Rate&nbsp; &nbsp;% (n/N)</p></td><td><p>Treatment Difference&nbsp;&nbsp;(95% CI)</p></td></tr><tr><td colspan="3"><p>Study 068</p></td></tr><tr><td><p>FLOXAG 320 mg x 5 days</p></td><td><p>86.0 (239/278)</p></td><td rowspan="2"><p>1.2 (-4.7, 7.0)</p></td></tr><tr><td><p>Clarithromycin 500 mg BID x 7 days</p></td><td><p>84.8 (240/283)</p></td></tr><tr><td colspan="3"><p>Study 070</p></td></tr><tr><td><p>FLOXAG 320 mg x 5 days</p></td><td><p>93.6 (247/264)</p></td><td rowspan="2"><p>0.4 (-3.9, 4.6)</p></td></tr><tr><td><p>Amoxicillin/clavulanate 500 mg/125 mg TID x 7 days</p></td><td><p>93.2 (248/266)</p></td></tr><tr><td colspan="3"><p>Study 212</p></td></tr><tr><td><p>FLOXAG 320 mg x 5 days</p></td><td><p>88.2 (134/152)</p></td><td rowspan="2"><p>3.1 (-4.7, 10.7)</p></td></tr><tr><td><p>Levofloxacin 500 mg x 7 days</p></td><td><p>85.1 (126/148)</p></td></tr></tbody></table><p>Community Acquired Pneumonia (CAP)</p><p>5 Day Treatment Regimen</p><p>To evaluate the safety and efficacy of a 5-day course of FLOXAG, 510&nbsp;outpatient&nbsp;and hospitalized adults with clinically and radiologically determined mild to moderate community-acquired&nbsp;pneumonia&nbsp;were clinically evaluated in a double-blind, randomized,&nbsp;prospective, multicenter study comparing FLOXAG 320 mg for five days to FLOXAG 320 mg for seven days (Study OP-634-001). Clinical success rates in the clinically evaluable population were 95.0% in the 5 day group and 92.1% in the 7 day group.</p><p>Table 7. Clinical Response at Follow-Up (Test of Cure): Study OP-634-001</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Drug Regimen</p></td><td><p>Success Rate % (n/N)</p></td><td><p>Treatment Difference (95% CI)</p></td></tr><tr><td colspan="3"><p>Study OP-634-001</p></td></tr><tr><td><p>FLOXAG 320 mg x 5 days</p></td><td><p>95.0 (230/242)</p></td><td rowspan="2"><p>3.0 (-1.5, 7.4)</p></td></tr><tr><td><p>FLOXAG 320 mg x 7 days</p></td><td><p>92.1 (209/227)</p></td></tr></tbody></table><p>The microbiological efficacy of the 5-day regimen was documented for pathogens listed in Table 8 below.</p><p>Table 8. Bacterial Eradication by Pathogen for Patients Treated with FLOXAG in Study OP-634-001</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td colspan="2"><p>5-day</p></td><td colspan="2"><p>7-day</p></td></tr><tr><td><p>Pathogen</p></td><td><p>n/N</p></td><td><p>%</p></td><td><p>n/N</p></td><td><p>%</p></td></tr><tr><td><p><em>Streptococcus pneumoniae</em></p></td><td><p>26/26</p></td><td><p>100</p></td><td><p>34/40</p></td><td><p>85.0</p></td></tr><tr><td><p><em>Mycoplasma pneumoniae</em></p></td><td><p>22/25</p></td><td><p>88.0</p></td><td><p>19/20</p></td><td><p>95.0</p></td></tr><tr><td><p><em>Haemophilus influenzae</em></p></td><td><p>21/22</p></td><td><p>95.5</p></td><td><p>18/18</p></td><td><p>100</p></td></tr><tr><td><p><em>Chlamydia pneumoniae</em></p></td><td><p>17/18</p></td><td><p>94.4</p></td><td><p>30/31</p></td><td><p>96.8</p></td></tr></tbody></table><p>7 Day Treatment Regimen</p><p>Previous clinical studies evaluated the efficacy of FLOXAG in a 7-day treatment of CAP in adults.&nbsp; This clinical program consisted of three double-blind, randomized, actively-controlled clinical studies (studies 011, 012, and 049) and one open-label, actively-controlled study (study 185).&nbsp; In addition, two uncontrolled studies (studies 061 and 287) were conducted.&nbsp; Three of the studies, controlled study 011 and the uncontrolled studies, had a fixed 7-day duration of treatment for FLOXAG. Controlled study 011 compared a 7-day course of FLOXAG with a 10-day treatment course of &nbsp;amoxicillin/clavulanate (1g/125 mg TID) and clinical success rates were similar between treatment arms.&nbsp; The results of comparative studies 049, 185, and 012 were supportive although treatment duration could have been 7 to 14 days.&nbsp; The results of the clinical studies with a fixed 7-day duration of FLOXAG are shown in Table 9.</p><p>Table 9. Clinical Response at Follow-Up (Test of Cure): CAP Studies with a Fixed 7-day Duration of Treatment</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Drug Regimen</p></td><td><p>Success Rate % (n/N)</p></td><td><p>Treatment Difference &nbsp;(95% CI)*</p></td></tr><tr><td colspan="2"><p>Study 011</p></td><td>&nbsp;</td></tr><tr><td><p>FLOXAG 320 mg x 7 days</p></td><td><p>88.7 (102/115)</p></td><td rowspan="2"><p>1.1 (-7.3, 9.5)</p></td></tr><tr><td><p>Amoxicillin/clavulanate 1 g/125 mg TID x 10 days</p></td><td><p>87.6 (99/113)</p></td></tr><tr><td colspan="2"><p>Study 061</p></td><td>&nbsp;</td></tr><tr><td><p>FLOXAG 320 mg x 7 days</p></td><td><p>91.7 (154/168)</p></td><td><p>(86.1, 95.2)</p></td></tr><tr><td colspan="2"><p>Study 287</p></td><td>&nbsp;</td></tr><tr><td><p>FLOXAG 320 mg x 7 days</p></td><td><p>89.8 (132/147)</p></td><td><p>(84.9, 94.7)</p></td></tr></tbody></table><p>*For uncontrolled studies, the 95% CI around the success rate is shown</p><p>The combined bacterial eradication rates for patients treated with a fixed 7-day treatment regimen of FLOXAG are shown in Table 10.</p><p>Table 10. Bacterial Eradication by Pathogen for Patients Treated with FLOXAG in Studies with a Fixed 7-day Duration of Treatment</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Pathogen</p></td><td><p>n/N</p></td><td><p>%</p></td></tr><tr><td><p><em>S. pneumoniae</em></p></td><td><p>102/117</p></td><td><p>87.2</p></td></tr><tr><td><p><em>M. pneumoniae</em></p></td><td><p>40/42</p></td><td><p>95.2</p></td></tr><tr><td><p><em>H. influenzae</em></p></td><td><p>48/53</p></td><td><p>90.6</p></td></tr><tr><td><p><em>C. pneumoniae</em></p></td><td><p>43/45</p></td><td><p>95.6</p></td></tr><tr><td><p><em>K. pneumoniae</em></p></td><td><p>18/20</p></td><td><p>90.0</p></td></tr><tr><td><p><em>M. catarrhalis</em></p></td><td><p>11/12</p></td><td><p>91.7</p></td></tr></tbody></table><p>7 Day Treatment Regimen of Community-Acquired Pneumonia Due to Multi-Drug Resistant Streptococcus Pneumoniae (MDRSP)</p><p>FLOXAG was also effective in the treatment of CAP due to multi-drug resistant&nbsp;Streptococcus pneumoniae&nbsp;(MDRSP*).&nbsp; Of 35 patients with MDRSP treated for 7 days, 29 (82.9%) achieved clinical and bacteriological success at follow-up.&nbsp; The clinical and bacteriological success for the 35 patients with MDRSP isolates are shown in Table 11. &nbsp;</p><p>*MDRSP: multi-drug resistant&nbsp;Streptococcus pneumoniae, includes isolates previously known as PRSP (penicillin-resistant&nbsp;Streptococcus pneumoniae), and are strains resistant to two or more of the following antibiotics: penicillin (MIC &ge;2 &micro;g/mL), 2nd generation cephalosporins (e.g., cefuroxime), macrolides, tetracyclines and trimethoprim/sulfamethoxazole.</p><p>Table 11. Clinical and Bacteriological Success for 35 Patients Treated with FLOXAG in CAP Studies with a 7-day Duration of Treatment for MDRSP</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p>Screening Susceptibility</p></td><td colspan="2"><p>Clinical Success</p></td><td colspan="2"><p>Bacteriological Success</p></td></tr><tr><td><p>n/N<sup>a</sup>&nbsp;&nbsp;</p></td><td><p>%</p></td><td><p>n/N<sup>b</sup>&nbsp;&nbsp;</p></td><td><p>%</p></td></tr><tr><td><p>Penicillin-resistant</p></td><td><p>15/16</p></td><td><p>93.8</p></td><td><p>15/16</p></td><td><p>93.8</p></td></tr><tr><td><p>2nd &nbsp;generation cephalosporin-resistant</p></td><td><p>20/22</p></td><td><p>90.9</p></td><td><p>20/22</p></td><td><p>90.9</p></td></tr><tr><td><p>Macrolide-resistantc &nbsp;</p></td><td><p>24/28</p></td><td><p>85.7</p></td><td><p>23/28</p></td><td><p>82.1</p></td></tr><tr><td><p>Trimethoprim/sulfamethoxazole-resistant</p></td><td><p>23/26</p></td><td><p>88.5</p></td><td><p>23/26</p></td><td><p>88.5</p></td></tr><tr><td><p>Tetracycline-resistant</p></td><td><p>21/27</p></td><td><p>77.8</p></td><td><p>20/27</p></td><td><p>74.1</p></td></tr><tr><td colspan="5"><p><sup>a</sup>n = the number of patients successfully treated; N = number of patients with MDRSP<br /><sup>b</sup>n = the number of bacteriological isolates successfully treated; N = number of isolates studied<br />&nbsp;<sup>c</sup>Macrolide antibiotics tested include clarithromycin and erythromycin</p></td></tr></tbody></table><p>Not all isolates were resistant to all antimicrobial classes tested.&nbsp; Success and eradication rates are summarized in Table 12 below.</p><p>Table 12. Resistant&nbsp;Streptococcus pneumoniae&nbsp;Clinical Success and Bacteriological Eradication Rates</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p>S. pneumoniae with MDRSP</p></td><td colspan="2"><p>Clinical Cure Rate</p></td><td colspan="2"><p>Bacteriological Eradication Rate</p></td></tr><tr><td><p>n/N</p></td><td><p>%</p></td><td><p>n/N</p></td><td><p>%</p></td></tr><tr><td><p>Resistant to 2 antimicrobials</p></td><td><p>8/11</p></td><td><p>72.7</p></td><td><p>7/11</p></td><td><p>63.6</p></td></tr><tr><td><p>Resistant to 3 antimicrobials</p></td><td><p>5/7</p></td><td><p>71.4</p></td><td><p>5/7</p></td><td><p>71.4</p></td></tr><tr><td><p>Resistant to 4 antimicrobials</p></td><td><p>8/9</p></td><td><p>88.9</p></td><td><p>8/9</p></td><td><p>88.9</p></td></tr><tr><td><p>Resistant to 5 antimicrobials</p></td><td><p>8/8</p></td><td><p>100</p></td><td><p>8/8</p></td><td><p>100</p></td></tr><tr><td><p>Bacteremia with MDRSP</p></td><td><p>3/3</p></td><td><p>100</p></td><td><p>3/3</p></td><td><p>100</p></td></tr></tbody></table><p>Clinical Safety Study of Rash</p><p>To further characterize gemifloxacin-associated rash, which in early clinical studies appeared to be associated with age less than 40 and female gender, a clinical pharmacology study was conducted. &nbsp;The study enrolled 1,011 healthy female volunteers less than 40 years of age.&nbsp; Subjects were randomized in a 5:1 ratio to receive either FLOXAG 320 mg PO daily (819 subjects) or ciprofloxacin 500 mg PO twice daily for 10 days (164 subjects). This study was designed to enroll subjects at a high risk for rash (women &lt;40 years of age and dosing beyond the recommended duration of therapy for &nbsp;FLOXAG [10 days]) and over estimates the risk to patients taking FLOXAG as prescribed.&nbsp; Subjects who received FLOXAG were 7 times more likely to develop rash than those who received ciprofloxacin.&nbsp; Of the 260 rashes in subjects receiving FLOXAG, the majority of rashes were maculopapular and of mild to moderate severity; 7% of the rashes were reported as severe, and severity appeared to correlate with the extent of the rash. In 68% of the subjects reporting a severe rash and approximately 25% of all those reporting rash, &gt;60% of the&nbsp;body surface area&nbsp;was involved; the characteristics of the rash were otherwise indistinguishable from those subjects reporting a mild rash.&nbsp; The histopathology was consistent with the clinical observation of uncomplicated exanthematous morbilliform eruption.&nbsp; Approximately 11% of the rashes were described as being urticaria-like.&nbsp; There were no documented cases of hypersensitivity syndrome or findings suggestive of&nbsp;angioedema&nbsp;or other serious&nbsp;cutaneous&nbsp;reactions.</p><p>The majority of rashes (81.9%) occurred on days 8 through 10 of the planned 10 day course of FLOXAG; 2.7% of rash events occurred within one day of the start of dosing. The median duration of rash was 6 days.&nbsp; The rash resolved without treatment in the majority of subjects.&nbsp; Approximately 19% received&nbsp;antihistamines&nbsp;and 5% received steroids, although the therapeutic benefit of these therapies is uncertain.</p><p>In the second part of this study after a 4 to 6 week wash out period, subjects developing a rash on FLOXAG were treated with ciprofloxacin (n=136) or placebo (n=50); 5.9% developed rash when treated with ciprofloxacin and 2.0% developed rash when treated with placebo.&nbsp; The cross sensitization rate to other fluoroquinolones was not evaluated in this clinical study.&nbsp; There was no evidence of&nbsp;sub-clinical sensitization to FLOXAG on a second exposure (i.e., subjects who had not developed a rash to FLOXAG in the first part of the study were not at higher risk of developing a rash to FLOXAG with a second exposure).</p><p>There was no relationship between the incidence of rash and systemic exposure (Cmax and AUC) to either gemifloxacin or its major metabolite, N-acetyl gemifloxacin.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacokinetics</p><p>The pharmacokinetics of gemifloxacin are approximately linear over the dose range from 40 mg to 640 mg.&nbsp; There was minimal accumulation of gemifloxacin following multiple oral doses up to 640 mg a day for 7 days (mean accumulation &lt;20%).&nbsp; Following repeat oral administration of 320 mg gemifloxacin once daily, steady-state is achieved by the third day of dosing.</p><p>&nbsp;</p><p>Absorption and Bioavailability</p><p>Gemifloxacin, given as an oral tablet, is rapidly absorbed from the gastrointestinal tract. Peak plasma concentrations of gemifloxacin were observed between 0.5 and 2 hours following oral tablet&nbsp; administration and the absolute bioavailability of the 320 mg tablet averaged approximately 71% (95% CI 60%-84%). Following repeat oral doses of 320 mg to healthy subjects, the mean&nbsp; &Acirc;&plusmn;&nbsp; SD maximal gemifloxacin plasma concentrations (Cmax) and systemic drug exposure (AUC (0-24)) were 1.61 &Acirc;&plusmn;&nbsp; 0.51 &micro;g/mL (range 0.70-2.62 &micro;g/mL) and 9.93 &Acirc;&plusmn;&nbsp; 3.07 &micro;g&bull;hr/mL (range 4.71-20.1 &micro;g&bull;hr/mL), respectively. In patients with respiratory and urinary tract infections (n=1423), similar estimates of systemic drug exposure were determined using a population pharmacokinetics analysis (geometric mean AUC (0-24), 8.36 &micro;g&bull;hr/mL; range 3.2 to 47.7 &micro;g&bull;hr/mL).</p><p>The pharmacokinetics of gemifloxacin were not significantly altered when a 320 mg dose was administered with a high-fat meal.&nbsp; Therefore FLOXAG tablets may be administered without regard to meals.</p><p>Distribution</p><p>In vitro binding of gemifloxacin to plasma proteins in healthy subjects is approximately 60 to 70% and is concentration independent. After repeated doses, the in vivo plasma protein binding in healthy elderly and young subjects ranged from 55% to 73% and was unaffected by age. Renal impairment does not significantly affect the protein binding of gemifloxacin.&nbsp; The blood-to-plasma concentration ratio of gemifloxacin was 1.2:1.&nbsp; The geometric mean for Vdss/F is 4.18 L/kg (range, 1.66 &ldquo; 12.12 L/kg).</p><p>Gemifloxacin is widely distributed throughout the body after oral administration.&nbsp; Concentrations of gemifloxacin in bronchoalveolar lavage fluid exceed those in the plasma.&nbsp; Gemifloxacinpenetrates well into lung tissue and fluids.&nbsp; After five daily doses of 320 mg gemifloxacin, concentrations in plasma, bronchoalveolar macrophages, epithelial lining fluid and bronchial mucosa at approximately 2 hours were as in Table 1.</p><table border="1" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td><p>Tissue</p></td><td><p>Concentration &nbsp;(mean &Acirc;&plusmn; SD)</p></td><td><p>Ratio compared with plasma (mean &Acirc;&plusmn; SD)</p></td></tr><tr><td><p>Plasma</p></td><td><p>1.40 (0.442) &micro;g/mL</p></td><td><p>-</p></td></tr><tr><td><p>Bronchoalveolar Macrophages</p></td><td><p>107 (77) &micro;g/g</p></td><td><p>90.5 (106.3)</p></td></tr><tr><td><p>Epithelial Lining Fluid</p></td><td><p>2.69 (1.96) &micro;g/mL</p></td><td><p>1.99 (1.32)</p></td></tr><tr><td><p>Bronchial Mucosa</p></td><td><p>9.52 (5.15) &micro;g/g</p></td><td><p>7.21 (4.03)</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Table 1. Gemifloxacin Concentrations in Plasma and Tissues (320 mg Oral Dosing)</p><p>Metabolism</p><p>Gemifloxacin is metabolized to a limited extent by the liver. The unchanged compound is the predominant drug-related component detected in plasma (approximately 65%) up to 4 hours after dosing. All metabolites formed are minor (&lt;10% of the administered oral dose); the principal ones are N-acetyl gemifloxacin, the E-isomer of gemifloxacin and the carbamyl glucuronide of gemifloxacin.&nbsp; Cytochrome P450 enzymes do not play an important role in gemifloxacin metabolism, and the metabolic activity of these enzymes is not significantly inhibited by gemifloxacin.</p><p>&nbsp;</p><p>Excretion</p><p>Gemifloxacin and its metabolites are excreted via dual routes of excretion.&nbsp; Following oral administration of gemifloxacin to healthy subjects, a mean (&Acirc;&plusmn;&nbsp; SD) of 61 &Acirc;&plusmn; 9.5% of the dose was excreted in the feces and 36 &Acirc;&plusmn; 9.3% in the urine as unchanged drug and metabolites.&nbsp; The mean (&Acirc;&plusmn;&nbsp; SD) renal clearance following repeat doses of 320 mg was approximately 11.6 &Acirc;&plusmn; 3.9 L/hr (range 4.6-17.6 L/hr), which indicates active secretion is involved in the renal excretion of gemifloxacin.&nbsp; The mean (&Acirc;&plusmn;&nbsp; SD) plasma elimination half-life at steady state following 320 mg to healthy subjects was approximately 7 &Acirc;&plusmn; 2 hours (range 4-12 hours).&nbsp;</p><p>&nbsp;</p><p>Special Populations</p><p>Pediatric: The pharmacokinetics of gemifloxacin in pediatric subjects have not been studied.</p><p>&nbsp;</p><p>Geriatric: In adult subjects, the pharmacokinetics of gemifloxacin are not affected by age.</p><p>&nbsp;</p><p>Gender: There are no significant differences between gemifloxacin pharmacokinetics in males and females when differences in body weight are taken into account.&nbsp; Population pharmacokinetic studies indicated that following administration of 320 mg gemifloxacin, AUC values were approximately 10% higher in healthy female patients compared to males.&nbsp; Males and females had mean AUC values of 7.98 &micro;g&bull;hr/mL (range, 3.21 &ldquo;42.71 &micro;g&bull;hr/mL) and 8.80 &micro;g&bull;hr/mL (range, 3.33 to 47.73 &micro;g&bull;hr/mL), respectively.&nbsp; No gemifloxacin dosage adjustment based on gender is necessary.</p><p>&nbsp;</p><p>Hepatic Insufficiency: The pharmacokinetics following a single 320 mg dose of gemifloxacin were studied in patients with mild (Child-Pugh Class A) to moderate (Child-Pugh Class B) liver disease.</p><p>&nbsp;</p><p>There was a mean increase in AUC (0-inf) of 34% and a mean increase in Cmax of 25% in these patients with hepatic impairment compared to healthy volunteers.</p><p>&nbsp;</p><p>The pharmacokinetics of a single 320 mg dose of gemifloxacin were also studied in patients with severe hepatic impairment (Child-Pugh Class C).&nbsp; There was a mean increase in AUC (0-inf) of 45% and a mean increase in Cmax of 41% in these subjects with hepatic impairment compared to healthy volunteers.</p><p>&nbsp;</p><p>These average pharmacokinetic increases are not considered to be clinically significant.&nbsp; There was no significant change in plasma elimination half-life in the mild, moderate or severe</p><p>&nbsp;</p><p>hepatic impairment patients.&nbsp; No dosage adjustment is recommended in patients with mild (Child-Pugh Class A), moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment. (See DOSAGE AND ADMINISTRATION.)</p><p>&nbsp;</p><p>Renal Insufficiency: Results from population pharmacokinetic and clinical pharmacology studies with repeated 320 mg doses indicate the clearance of gemifloxacin is reduced and the plasma elimination is prolonged, leading to an average increase in AUC values of approximately 70% in patients with renal insufficiency. In the pharmacokinetic studies, gemifloxacin Cmax was not significantly altered in subjects with renal insufficiency. Dose adjustment in patients with creatinine clearance &gt;40 mL/min is not required.&nbsp; Modification of the dosage is recommended for patients&nbsp; with creatinine clearance ?40 mL/min. (See DOSAGE AND ADMINISTRATION.)</p><p>&nbsp;</p><p>Hemodialysis removes approximately 20 to 30% of an oral dose of gemifloxacin from plasma.</p><p>&nbsp;</p><p>Photosensitivity Potential</p><p>In a study of the skin response to ultraviolet and visible radiation conducted in 40 healthy volunteers, the minimum erythematous dose (MED) was assessed following administration of either gemifloxacin 160 mg once daily, gemifloxacin 320 mg once daily, ciprofloxacin 500 mg BID, or placebo for 7 days.&nbsp; At 5 of the 6 wavelengths tested (295-430 nm), the photosensitivity potential of gemifloxacin was not statistically different from placebo.&nbsp; At 365 nm (UVA region), gemifloxacin showed a photosensitivity potential similar to that of ciprofloxacin 500 mg BID and the photosensitivity potential for both drugs were statistically greater than that of placebo.&nbsp; Photosensitivity reactions were reported rarely in clinical trials with gemifloxacin (0.039%).&nbsp; (See ADVERSE REACTIONS.)</p><p>&nbsp;</p><p>It is difficult to ascribe relative photosensitivity/phototoxicity among various fluoroquinolones during actual patient use because other factors play a role in determining a subject&trade;s susceptibility to this adverse event such as: a patient&trade;s skin pigmentation, frequency and duration of sun and artificial ultraviolet light (UV) exposure, wearing of sun screen and protective clothing, the use of other concomitant drugs and the dosage and duration of fluoroquinolone therapy. (See ADVERSE REACTIONS and ADVERSE REACTIONS: Post-Marketing Adverse Reactions.)</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>See (5.1 pharmacodynamic properties&amp;5.2 Pharmacokinetic properties)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Avicel PH101</p><p>Crospovidone NF</p><p>Croscarmellose Sodium type A</p><p>Sodium Lauryl Sulphate</p><p>Povidone 30</p><p>Ethanol Absolute</p><p>Avicel PH 102</p><p>Magnesium Stearate</p><p>Coating:</p><p>Hydroxypropyle methylcellulose</p><p>Titanium dioxide pharma grade</p><p>Purified talc</p><p>Polyethylene glycol MW 6000</p><p>Purified water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24Months/2 Years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A white to off-white color, oblong shaped, biconvex, film-coated tablet, engraved with &ldquo;517&rdquo; on one side and break line on the other side.</p><p>Each carton contains 5 or 7 Film-Coated tablets in Aluminum thin soft temper plain strips.</p><p>Not all pack sizes may be marketed</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SPIMACO
AlQassim pharmaceutical plant
Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                March 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>